Zacks Research Has Negative Estimate for Neogen Q3 Earnings

Neogen Corporation (NASDAQ:NEOG) – Stock analysts at Zacks Research cut their Q3 2026 earnings estimates for shares of Neogen in a research note issued to investors on Thursday, January 29th. Zacks Research analyst Team now expects that the company will earn $0.04 per share for the quarter, down from their prior forecast of $0.07. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s FY2026 earnings at $0.24 EPS, Q1 2027 earnings at $0.06 EPS, Q4 2027 earnings at $0.05 EPS and Q2 2028 earnings at $0.08 EPS.

Neogen (NASDAQ:NEOG) last posted its quarterly earnings data on Thursday, January 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03. Neogen had a negative net margin of 68.47% and a positive return on equity of 2.14%. The company had revenue of $224.69 million during the quarter, compared to the consensus estimate of $208.50 million. During the same period in the previous year, the firm posted $0.11 EPS. The firm’s revenue was down 2.9% compared to the same quarter last year.

A number of other analysts also recently weighed in on NEOG. CJS Securities upgraded Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Neogen in a research report on Monday, December 29th. Wall Street Zen lowered shares of Neogen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Guggenheim reaffirmed a “buy” rating and issued a $12.00 price objective (up previously from $8.00) on shares of Neogen in a research note on Friday, January 9th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $10.00 target price (up previously from $6.50) on shares of Neogen in a report on Monday, January 12th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $10.67.

Neogen Price Performance

NEOG opened at $10.27 on Monday. The company has a current ratio of 3.91, a quick ratio of 2.80 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $2.23 billion, a P/E ratio of -3.71 and a beta of 1.98. The stock has a 50-day moving average price of $7.91 and a 200-day moving average price of $6.46. Neogen has a 12-month low of $3.87 and a 12-month high of $10.90.

Hedge Funds Weigh In On Neogen

A number of hedge funds have recently modified their holdings of NEOG. AQR Capital Management LLC raised its stake in shares of Neogen by 217.0% during the first quarter. AQR Capital Management LLC now owns 52,410 shares of the company’s stock valued at $443,000 after acquiring an additional 35,878 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Neogen by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 129,813 shares of the company’s stock valued at $1,125,000 after purchasing an additional 5,638 shares during the last quarter. Jones Financial Companies Lllp raised its position in Neogen by 5,687.3% during the 1st quarter. Jones Financial Companies Lllp now owns 33,393 shares of the company’s stock valued at $290,000 after purchasing an additional 32,816 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Neogen by 14.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,678,493 shares of the company’s stock worth $14,553,000 after buying an additional 209,990 shares during the period. Finally, United Services Automobile Association bought a new stake in shares of Neogen in the 1st quarter worth approximately $112,000. Hedge funds and other institutional investors own 96.73% of the company’s stock.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.